Meyer Andrew Hollman's Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Sep 27, 2024
- Accession no.
- 0001415889-24-024078
- Filed
- Sep 27, 2024
- Trade date
- Sep 27, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.30M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meyer Andrew HollmanCIK 0001864159 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2024 | Common Stock | MOption exerciseAcquired | +50,000 | $4.21 | +$210,500 | 117,592 | Direct | |
| Sep 27, 2024 | Common Stock | SSaleDisposed | −50,000 | $45.96F2 | −$2,298,000 | 67,592 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2024 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 100,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.